

## AUSTRALIAN PI - NEUPOGEN® (FILGRASTIM)

### 1 NAME OF THE MEDICINE

NEUPOGEN® is the Amgen Inc. trademark for filgrastim (rbe), a recombinant methionyl human granulocyte colony stimulating factor.

### 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

NEUPOGEN is available in single use prefilled syringes and vials. The single use prefilled syringes contain either 300 µg or 480 µg filgrastim at a fill volume of 0.5 mL. The single use vials contain either 300 µg or 480 µg filgrastim at a fill volume of 1.0 mL or 1.6 mL, respectively.

For the full list of excipients, see Section 6.1 List of excipients.

### 3 PHARMACEUTICAL FORM

NEUPOGEN is a sterile, clear, colourless, preservative-free liquid for parenteral administration.

### 4 CLINICAL PARTICULARS

#### 4.1 Therapeutic indications

NEUPOGEN is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs in doses not usually requiring bone marrow transplantation.

NEUPOGEN is indicated for reducing the duration of neutropenia and clinical sequelae in patients undergoing induction and consolidation chemotherapy for acute myeloid leukaemia (AML).

NEUPOGEN is indicated for the mobilisation of autologous peripheral blood progenitor cells alone, or following myelosuppressive chemotherapy, in order to accelerate neutrophil and platelet recovery by infusion of such cells after myeloablative or myelosuppressive therapy in patients with non-myeloid malignancies.

NEUPOGEN is indicated for the mobilisation of peripheral blood progenitor cells, in normal volunteers, for use in allogeneic peripheral blood progenitor cell (PBPC) transplantation.

---

In patients receiving myeloablative chemotherapy, NEUPOGEN is indicated for reducing the duration of neutropenia and clinical sequelae following autologous or allogeneic bone marrow transplantation.

NEUPOGEN is indicated for chronic administration to increase neutrophil counts and to reduce the incidence and duration of infections in patients with severe chronic neutropenia (SCN).

NEUPOGEN is indicated in patients with HIV infection, for reversal of clinically significant neutropenia and subsequent maintenance of adequate neutrophil counts during treatment with antiviral and/or other myelosuppressive medications.

## **4.2 Dose and method of administration**

### **Cancer patients receiving standard-dose cytotoxic chemotherapy or induction/consolidation chemotherapy for acute myeloid leukaemia**

In adults and children receiving induction/consolidation chemotherapy for AML, the recommended starting dose is 5 µg/kg/day administered as a single daily subcutaneous (SC) injection.

In patients with non-myeloid malignancies receiving standard-dose cytotoxic chemotherapy, the recommended starting dose of NEUPOGEN is 5 µg/kg/day, administered as a single daily SC injection or short intravenous (IV) infusion (over 15 to 30 minutes). In phase 3 trials efficacy was observed at doses of 4 to 8 µg/kg/day.

NEUPOGEN should not be administered in the period 24 hours before to 24 hours after the administration of chemotherapy (see Section 4.4 Special warnings and precautions for use).

The duration of NEUPOGEN therapy needed to attenuate chemotherapy-induced neutropenia may be dependent on the myelosuppressive potential of the chemotherapy regimen employed. In patients with non-myeloid malignancies receiving standard-dose cytotoxic chemotherapy, NEUPOGEN should be administered daily for up to 2 weeks, until the Absolute Neutrophil Count (ANC) has reached  $10 \times 10^9/L$  following the expected chemotherapy-induced neutrophil nadir. In patients with AML receiving induction or consolidation chemotherapy, NEUPOGEN should be administered daily until the ANC has reached  $> 1.0 \times 10^9/L$  for 3 consecutive days or  $> 10 \times 10^9/L$  for 1 day following the expected chemotherapy-induced neutrophil nadir.

---

**Patients with non-myeloid malignancies receiving high-dose cytotoxic chemotherapy with autologous or allogeneic bone marrow or peripheral blood progenitor cell transplantation**

The recommended starting dose of NEUPOGEN is 10 µg/kg/day given by continuous SC infusion or by IV infusion over 4 to 24 hours. NEUPOGEN should be diluted in 25 to 50 mL of 5% glucose solution.

The first dose of NEUPOGEN should be administered not less than 24 hours following cytotoxic chemotherapy and within 24 hours of bone marrow or PBPC infusion.

Once the neutrophil nadir has been passed, the daily dose of NEUPOGEN should be titrated against the neutrophil response as follows:

Neutrophil Count	NEUPOGEN Dose Adjustment
When ANC > 1.0 x 10 <sup>9</sup> /L for 3 consecutive days	Reduce to 5 µg/kg/day (§see below)
Then, if ANC remains > 1.0 x 10 <sup>9</sup> /L for 3 consecutive days	Discontinue NEUPOGEN
If ANC decreases to < 1.0 x 10 <sup>9</sup> /L	Resume at 5 µg/kg/day

§ If the ANC decreases to < 1.0 x 10<sup>9</sup>/L at any time during the 5 µg/kg/day administration, NEUPOGEN should be increased to 10 µg/kg/day, and the above steps should then be followed.

ANC = absolute neutrophil count

**Patients with myeloid malignancies receiving high-dose cytotoxic chemotherapy with autologous or allogeneic bone marrow or peripheral blood progenitor cell transplantation**

Following transplant, the recommended dose of NEUPOGEN to be given to the recipient is 5 µg/kg/day until neutrophil recovery (up to 28 days).

When given post-transplantation, the first dose of NEUPOGEN should be administered at least 24 hours after cytotoxic chemotherapy and at least 24 hours after infusion of bone marrow or PBPCs.

**Autologous peripheral blood progenitor cell collection and therapy**

The recommended dose of NEUPOGEN for PBPC mobilisation when used alone is 10 µg/kg/day given as a single daily SC injection or a continuous 24 hour infusion. NEUPOGEN therapy should be given for at least 4 days before the first leukapheresis procedure and should be continued through to the day of the last leukapheresis

procedure. Collections should be commenced on day 5 and continued on consecutive days until the desired yield of haemopoietic progenitor cells is obtained. For PBPCs mobilised with NEUPOGEN alone, a schedule of leukapheresis collections on days 5, 6 and 7 of a 7-day treatment regimen has been found to be effective. In some patients with extensive prior chemotherapy, additional daily doses of NEUPOGEN may be required to support additional leukaphereses to reach the desired target yield of cells (see Section 4.4 Special warnings and precautions for use, Peripheral Blood Progenitor Cell Collection and Therapy).

The recommended dose of NEUPOGEN for PBPC mobilisation after myelosuppressive chemotherapy is 5 µg/kg/day given daily by SC injection from 24 hours after completion of chemotherapy until the expected neutrophil nadir is passed and the neutrophil count has recovered to the normal range. Leukapheresis should be commenced during the period when the ANC rises from  $< 0.5 \times 10^9/L$  to  $> 5.0 \times 10^9/L$ . Leukapheresis collection should be repeated on consecutive days until an adequate number of progenitor cells is obtained (see Section 4.4 Special warnings and precautions for use, Peripheral Blood Progenitor Cell Collection and Therapy).

In all clinical trials of NEUPOGEN for the mobilisation of PBPCs, NEUPOGEN was administered following infusion of the collected cells. In the randomised phase 3 study, patients received NEUPOGEN 5 µg/kg/day post-transplantation until a sustainable ANC ( $> 0.5 \times 10^9/L$ ) was reached (see Section 5.1 Pharmacodynamic properties, Clinical trials).

When given post-transplantation, the first dose of NEUPOGEN should be administered at least 24 hours after cytotoxic chemotherapy and at least 24 hours after infusion of PBPCs.

### **Allogeneic peripheral blood progenitor cell collection from normal donors**

For PBPC mobilisation in normal donors, NEUPOGEN should be administered at 10 µg/kg/day SC for 4 to 5 consecutive days. Leukapheresis should be started on day 5 and daily collections continued on day 6 in order to collect a target yield of  $4 \times 10^6$  CD34<sup>+</sup> cells/kg recipient bodyweight.

### **Patients with severe chronic neutropenia**

Care should be taken to confirm the diagnosis of SCN, which may be difficult to distinguish from myelodysplasia (MDS), before initiating NEUPOGEN therapy.

---

It is essential that serial Full Blood Counts (FBCs) with differential and platelet counts, and an evaluation of bone marrow morphology and karyotype be performed prior to initiation of NEUPOGEN therapy.

### **Starting dose**

Congenital Neutropenia: The recommended daily starting dose is 12 µg/kg SC every day (single or divided doses).

Idiopathic or cyclic neutropenia: The recommended daily starting dose is 5 µg/kg SC every day (single or divided doses).

NEUPOGEN may be administered SC as a single daily injection to increase and sustain the average neutrophil count above  $1.5 \times 10^9/L$ . Chronic daily administration is required to maintain an adequate neutrophil count.

### **Dose adjustment**

After 1 to 2 weeks of therapy, the initial dose may be doubled or halved. Subsequently, the dose may be individually adjusted not more than every 1 to 2 weeks to maintain the average neutrophil count between 1.5 and  $10 \times 10^9/L$ . The dose should be reduced if the ANC is persistently above  $10 \times 10^9/L$  for 1 to 2 weeks.

In clinical trials, 97% of patients who responded to treatment with NEUPOGEN were treated at doses  $\leq 24 \mu\text{g/kg/day}$ . In the SCN postmarketing surveillance study, the reported median daily doses of NEUPOGEN were: 6.0 µg/kg (congenital neutropenia), 2.1 µg/kg (cyclic neutropenia), and 1.2 µg/kg (idiopathic neutropenia). In rare instances, patients with congenital neutropenia have required doses of NEUPOGEN  $\geq 100 \mu\text{g/kg/day}$ .

### **Patients with HIV infection**

The recommended starting dose of NEUPOGEN is 1 µg/kg/day administered daily by SC injection with titration up to a maximum of 5 µg/kg/day until a normal neutrophil count is reached and can be maintained ( $\text{ANC} \geq 2.0 \times 10^9/L$ ). In clinical studies, 96% of patients responded to NEUPOGEN at these doses, achieving reversal of neutropenia in a median of 2 days.

In a small number of patients (2%), doses of up to 10 µg/kg/day were required to achieve reversal of neutropenia.

---

### **For Maintaining Neutrophil Counts**

When reversal of neutropenia has been achieved, the minimal effective dose of NEUPOGEN to maintain a normal neutrophil count should be established. Initial dose adjustment to 3 times weekly dosing with 300 µg/day by SC injection is recommended. Further dose adjustment may be necessary, as determined by the patient's ANC, to maintain the neutrophil count at  $\geq 2.0 \times 10^9/L$ . In clinical studies, dosing with 300 µg/day on 1 to 7 days per week was required to maintain the ANC  $\geq 2.0 \times 10^9/L$ , with the median dose frequency being 3 days per week. Long-term administration may be required to maintain the ANC  $\geq 2.0 \times 10^9/L$ . NEUPOGEN dosing should be reduced and then stopped if myelosuppressive medication is discontinued and there is no recurrence of neutropenia.

### **Dilution and sterile transfer**

NEUPOGEN vials should be used on 1 occasion only and any residue discarded (see Section 6.4 Special precautions for storage).

If required, NEUPOGEN may be diluted in 5% glucose. NEUPOGEN diluted to concentrations below 15 µg/mL should be protected from adsorption to plastic materials by addition of Albumin (Human) to a final concentration of 2 mg/mL. When diluted in 5% glucose or 5% glucose plus Albumin (Human), NEUPOGEN is compatible with glass and a variety of plastics including PVC, polyolefin and polypropylene.

Dilution to a final concentration of less than 5 µg/mL filgrastim is not recommended at any time. Infusion should be complete within 24 hours of the sterile dilution and transfer. See Section 6.4 Special precautions for storage, for details of storage of diluted NEUPOGEN.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If particulates or discoloration are observed, the container should not be used.

### **4.3 Contraindications**

NEUPOGEN is contraindicated in patients with known hypersensitivity to *E coli*-derived products, filgrastim, or any other component of the product.

---

## 4.4 Special warnings and precautions for use

### **General**

#### **Splenomegaly and splenic rupture**

Splenic rupture has been reported following administration of NEUPOGEN; some of these cases were fatal. Left upper abdominal pain and/or shoulder tip pain accompanied by rapid increase in spleen size should be carefully monitored due to the uncommon ( $\geq 1/1000$  and  $< 1/100$ ) but serious risk of splenic rupture.

#### **Patients with sickle cell disease**

Clinicians should use caution and monitor patients accordingly when administering NEUPOGEN to patients with sickle cell trait or sickle cell disease because of the reported association of NEUPOGEN with sickle cell crisis (in some cases fatal). Use of NEUPOGEN in patients with sickle cell disease should be considered only after careful evaluation of the potential risks and benefits.

#### **Thrombocytopenia**

Thrombocytopenia has been reported commonly ( $\geq 1/100$  and  $< 1/10$ ) in patients receiving NEUPOGEN. Regular monitoring of the platelet count is recommended.

#### **Acute respiratory distress syndrome**

There have been occasional reports of the occurrence of acute respiratory distress syndrome (ARDS) in patients receiving NEUPOGEN. Patients with a recent history of pulmonary infiltrates or pneumonia may be at higher risk. The onset of pulmonary signs, such as cough, fever and dyspnoea in association with radiological signs of lung infiltration and deterioration in pulmonary function may be preliminary signs leading to respiratory failure or ARDS. NEUPOGEN should be immediately discontinued and appropriate treatment given.

#### **Pulmonary Haemorrhage and Haemoptysis**

Pulmonary haemorrhage and haemoptysis requiring hospitalisation have been reported in G-CSF-treated healthy donors undergoing peripheral blood progenitor cell (PBPC) collection mobilisation. Haemoptysis resolved with discontinuation of G-CSF.

---

**Glomerulonephritis**

Glomerulonephritis has been reported in patients receiving NEUPOGEN. Generally, after dose reduction or withdrawal of NEUPOGEN, events of glomerulonephritis resolved. Monitoring of urinalysis is recommended.

**Myelodysplastic syndrome (MDS) and Acute Myeloid Leukaemia (AML) in patients with breast cancer.**

In the post-marketing observational study setting, MDS and AML have been associated with the use of filgrastim in conjunction with chemotherapy and/or radiotherapy in breast cancer patients. Monitor patients for signs and symptoms of MDS/AML in these settings. There has been limited association between the occurrence of MDS and AML and the use of filgrastim in conjunction with chemotherapy and/or radiotherapy in breast cancer patients.

**Use in myelodysplasia and leukaemia**

The safety and efficacy of NEUPOGEN administration in patients with MDS or chronic myeloid leukaemia (CML) receiving myelosuppressive chemotherapy without stem cell support have not been established.

Randomised studies of NEUPOGEN in patients undergoing chemotherapy for AML demonstrate no stimulation of disease as measured by remission rate, relapse and survival.

**Aortitis**

Aortitis has been reported in patients receiving NEUPOGEN and may present with generalised signs and symptoms such as fever and increased inflammatory markers. Consider aortitis in patients who develop these signs and symptoms without known aetiology.

**Record of trade name**

In order to improve the traceability of G-CSFs, the trade name of the administered product should be clearly recorded in the patient file.

**Cancer patients receiving myelosuppressive chemotherapy****Concurrent use with chemotherapy and radiotherapy**

The safety and efficacy of NEUPOGEN given concurrently with cytotoxic chemotherapy have not been established. Because of the potential sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy, the use of NEUPOGEN is not recommended in

---



the period 24 hours before to 24 hours after the administration of chemotherapy (see Section 4.2 Dose and method of administration).

No controlled study has been done to examine the combination of chemoradiotherapy and NEUPOGEN on platelet count in a suitable oncology setting. Therefore, until more definitive data are available, simultaneous use of NEUPOGEN with chemoradiation should be undertaken with caution.

### **Leukocytosis**

White blood cell (WBC) counts of  $100 \times 10^9/L$  or greater were observed in approximately 2% of patients receiving NEUPOGEN at doses above  $5 \mu\text{g/kg/day}$ . There were no reports of adverse events associated with this degree of leukocytosis. In order to avoid the potential complications of excessive leukocytosis, a FBC is recommended twice per week during NEUPOGEN therapy (see Section 4.4 Special warnings and precautions for use, Laboratory monitoring).

### **Premature discontinuation of NEUPOGEN therapy**

A transient increase in neutrophil counts is typically seen 1 to 2 days after initiation of NEUPOGEN therapy. However, for a sustained therapeutic response, NEUPOGEN therapy should be continued until the post nadir ANC reaches  $10 \times 10^9/L$ . Therefore, the premature discontinuation of NEUPOGEN therapy, prior to the time of recovery from the expected neutrophil nadir, is generally not recommended (see Section 4.2 Dose and method of administration).

### **Risks associated with increased doses of chemotherapy**

In studies of NEUPOGEN administration following chemotherapy, most reported side effects were consistent with those usually seen as a result of cytotoxic chemotherapy (see Section 4.8 Adverse effects (undesirable effects)). Because of the potential of receiving higher doses of chemotherapy (i.e. full doses on the prescribed schedule for a longer period), the patient may be at greater risk of thrombocytopenia which should be monitored carefully. Anaemia and non-haematological consequences of increased chemotherapy doses (please refer to the prescribing information of the specific chemotherapy agents used) also may occur. Regular monitoring of the haematocrit and platelet count is recommended. Furthermore, care should be exercised in the administration of NEUPOGEN in conjunction with drugs known to lower the platelet count and in the presence of moderate or severe organ impairment. Thrombocytopenia may be more severe than normal in later courses of chemotherapy.

---

The use of NEUPOGEN-mobilised PBPCs has been shown to reduce the depth and duration of thrombocytopenia following myelosuppressive or myeloablative chemotherapy.

### **Peripheral blood progenitor cell collection and therapy**

#### **Mobilisation**

There are no prospectively randomised comparisons of the 2 recommended mobilisation methods (filgrastim alone, or in combination with myelosuppressive chemotherapy) within the same patient population. The degree of variation between both different patient groups and results of laboratory assays of CD34<sup>+</sup> cells means that direct comparison between different studies is difficult and an optimum method can not yet be recommended. The choice of mobilisation method should be considered in relation to the overall objectives of treatment for an individual patient.

#### **Assessment of progenitor cell yields**

In assessing the number of progenitor cells harvested in patients treated with NEUPOGEN, particular attention should be paid to the method of quantitation. The results of flow cytometric analysis of CD34<sup>+</sup> cell numbers vary depending on the precise methodology used. Recommendations for minimum acceptable progenitor cell yield based on studies using methods other than that of the reporting laboratory need to be interpreted with caution.

Statistical analysis of the relationship between the number of CD34<sup>+</sup> cells infused and the rate of platelet recovery after high-dose chemotherapy indicates a complex but continuous relationship, with the probability of more rapid platelet recovery increasing as the CD34<sup>+</sup> cell yield increases.

Currently, the minimum acceptable yield of CD34<sup>+</sup> cells is not well defined. The recommendation of a minimum yield of  $\geq 2 \times 10^6$  CD34<sup>+</sup> cells/kg is based on published experience resulting in adequate haematologic reconstitution.

#### **Prior exposure to cytotoxic agents**

Patients who have undergone very extensive prior myelosuppressive therapy may not show sufficient mobilisation of PBPCs to achieve the recommended minimum yield ( $\geq 2 \times 10^6$  CD34<sup>+</sup> cells/kg) or acceleration of platelet recovery, to the same degree. When PBPC transplantation is envisaged it is advisable to plan the stem cell mobilisation procedure early in the treatment course of the patient. Particular attention should be

---

paid to the number of progenitor cells mobilised in such patients *before* the administration of high-dose chemotherapy.

In one phase 2 study in heavily pretreated patients with acute lymphoblastic leukaemia, non-Hodgkin's lymphoma or Hodgkin's disease, no increased yield of progenitor cells was demonstrated by increasing the dose of filgrastim beyond that recommended.

If yields are inadequate, as measured by the criterion above, alternative forms of treatment not requiring progenitor cell support should be considered.

Some cytotoxic agents exhibit particular toxicities to the haemopoietic progenitor pool and may adversely affect progenitor cell mobilisation. Agents such as melphalan, carmustine (BCNU) and carboplatin, when administered over prolonged periods prior to attempts at progenitor cell mobilisation, may reduce progenitor cell yield. Nevertheless, the administration of melphalan, carboplatin or BCNU together with NEUPOGEN, has been shown to be effective for progenitor cell mobilisation.

### **Leukocytosis**

During the period of administration of NEUPOGEN for PBPC mobilisation in cancer patients, discontinuation of NEUPOGEN is appropriate if the leukocyte count rises to  $> 100 \times 10^9/L$ .

### **Tumour contamination of bone marrow and leukapheresis products**

Some studies of patient bone marrow and leukapheresis products have demonstrated the presence of malignant cells. While the possibility exists for tumour cells to be released from the marrow during mobilisation of PBPCs and subsequently collected in the leukapheresis product, in most of the studies, leukapheresis products appear to be less contaminated than bone marrow from the same patient. The effect of reinfusion of tumour cells has not been well studied and the limited data available are inconclusive.

### **Normal donors undergoing peripheral blood progenitor cell mobilisation**

Mobilisation of PBPC does not provide a direct clinical benefit to normal donors and should only be considered for the purposes of allogeneic stem cell transplantation.

PBPC mobilisation should be considered only in donors who meet normal clinical and laboratory eligibility criteria for stem cell donation with special attention to haematological values and infectious disease.

The safety and efficacy of NEUPOGEN has not been assessed in normal donors  $< 16$  years or  $> 60$  years.

---

Transient thrombocytopenia (platelets  $< 100 \times 10^9/L$ ) following NEUPOGEN administration and leukapheresis was observed in 35% of subjects studied. Among these, 2 cases of platelets  $< 50 \times 10^9/L$  were reported and attributed to the leukapheresis procedure.

If more than 1 leukapheresis is required, particular attention should be paid to donors with platelets  $< 100 \times 10^9/L$  prior to leukapheresis; in general apheresis should not be performed if platelets are  $< 75 \times 10^9/L$ .

Leukapheresis should not be performed in donors who are anticoagulated or who have known defects in haemostasis.

NEUPOGEN administration should be discontinued or its dosage should be reduced if the leukocyte counts rise to  $> 100 \times 10^9/L$ .

Donors who receive NEUPOGEN for PBPC mobilisation should be monitored until haematological indices return to normal.

Insertion of a central venous catheter should be avoided where possible, and therefore consideration should be given to the adequacy of venous access when selecting donors.

Long-term safety follow-up of donors is ongoing. For up to 4 years, there have been no reports of abnormal haematopoiesis in normal donors. Nevertheless, a risk of promotion of a malignant myeloid clone can not be excluded. It is recommended that the apheresis centre perform a systematic record and tracking of the stem cell donors to ensure monitoring of long-term safety.

There have been uncommon ( $\geq 1/1000$  and  $< 1/100$ ) cases of splenic rupture reported in healthy donors following administration of G-CSFs. In donors experiencing left upper abdominal pain and/or shoulder tip pain and rapid increase in spleen size, the risk of splenic rupture should be considered and carefully monitored.

In normal donors, pulmonary adverse events (haemoptysis, lung infiltration) have been reported.

### **Recipients of allogeneic peripheral blood progenitor stem cells mobilised with NEUPOGEN**

Current data indicate that immunological interactions between the allogeneic PBPC graft and the recipient may be associated with an increased risk of acute and chronic Graft versus Host Disease (GvHD) when compared with bone marrow transplantation.

---

## **Patients with severe chronic neutropenia**

### **Diagnosis of SCN**

Care should be taken to confirm the diagnosis of SCN, which may be difficult to distinguish from MDS, before initiating NEUPOGEN therapy. The safety and efficacy of NEUPOGEN in the treatment of neutropenia or pancytopenia due to other haemopoietic disorders (e.g. myelodysplastic disorders or myeloid leukaemia) have not been established.

It is, therefore, essential that serial FBCs with differential and platelet counts and an evaluation of bone marrow morphology and karyotype be performed prior to initiation of NEUPOGEN therapy. The use of NEUPOGEN prior to diagnostic confirmation of SCN may mask neutropenia as a diagnostic sign of a disease process other than SCN and prevent adequate evaluation and appropriate treatment of the underlying condition causing the neutropenia.

### **Myelodysplasia and acute myeloid leukaemia**

Cytogenetic abnormalities, transformation to MDS and AML have been observed in patients treated with NEUPOGEN for SCN. Myelodysplasia and AML have been reported to occur in the natural history of SCN without cytokine therapy. Based on available data including a postmarketing surveillance study, the risk of developing MDS and AML appears to be confined to the subset of patients with congenital neutropenia (see Section 4.8 Adverse effects (undesirable effects)). Abnormal cytogenetics have been associated with the development of myeloid leukaemia. The effect of NEUPOGEN on the development of abnormal cytogenetics and the effect of continued NEUPOGEN administration in patients with abnormal cytogenetics or MDS are unknown. If a patient with SCN develops abnormal cytogenetics or MDS, the risks and benefits of continuing NEUPOGEN should be carefully considered.

## **Patients with HIV infection**

### **Risks associated with increased doses of myelosuppressive medications**

Treatment with NEUPOGEN alone does not preclude thrombocytopenia and anaemia due to myelosuppressive medications. As a result of the potential to receive higher doses or a greater number of medications with NEUPOGEN therapy, the patient may be at higher risk of developing thrombocytopenia and anaemia. Regular monitoring of blood counts is recommended (see Section 4.4 Special warnings and precautions for use, Laboratory monitoring)

---

### **Infections and malignancies causing myelosuppression**

Neutropenia may also be due to bone marrow infiltrating opportunistic infections such as *Mycobacterium avium* complex or malignancies such as lymphoma. In patients with known bone marrow infiltrating infection or malignancy, consideration should be given to appropriate therapy for treatment of the underlying condition. The effects of NEUPOGEN on neutropenia due to bone marrow infiltrating infection or malignancy have not been well established.

### **Laboratory monitoring**

#### **Immunogenicity**

As with all therapeutic proteins, there is potential for immunogenicity. Rates of antibody generation against filgrastim are generally low. Binding antibodies do develop but have not been associated with neutralising activity or adverse clinical consequences.

The detection of antibody formation is dependent on the sensitivity and specificity of the assay. The observed incidence of antibody positivity (including neutralising antibody) in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications and underlying disease, therefore comparison of the incidence of antibodies to other products may be misleading.

#### **Cancer patients receiving myelosuppressive chemotherapy**

An FBC, haematocrit and platelet count should be obtained prior to chemotherapy and at regular intervals (twice per week) during NEUPOGEN therapy. Following cytotoxic chemotherapy, the neutrophil nadir occurred earlier during cycles when NEUPOGEN was administered and WBC differentials demonstrated a left shift, including the appearance of promyelocytes and myeloblasts. In addition, the duration of severe neutropenia was reduced and was followed by an accelerated recovery in the neutrophil counts. Therefore, regular monitoring of WBC counts, particularly at the time of the recovery from the post chemotherapy nadir is recommended in order to avoid excessive leukocytosis (see Section 4.2 Dose and method of administration).

#### **Peripheral blood progenitor cell collection and therapy**

After 4 days of NEUPOGEN treatment for PBPC mobilisation, neutrophil counts should be monitored. Frequent complete blood counts and platelet counts are recommended following infusion of PBPCs, at least 3 times per week until haemopoietic recovery.

---

The mobilisation and apheresis procedures should be performed in collaboration with an oncology-haematology centre with acceptable experience in this field and where the monitoring of haemopoietic progenitor cells can be appropriately performed and interpreted (see Section 4.4 Special warnings and precautions for use).

### **Patients with severe chronic neutropenia**

During the initial 4 weeks of NEUPOGEN therapy and for 2 weeks following any dose adjustment, an FBC with differential count should be performed twice weekly. Once a patient is clinically stable, an FBC with differential count and platelet determination should be performed monthly during the first year of treatment. Thereafter, if clinically stable, routine monitoring with regular FBCs (i.e. as clinically indicated but at least quarterly) is recommended. Additionally, for those patients with congenital neutropenia, annual bone marrow and cytogenetic evaluations should be performed throughout the duration of treatment (see Section 4.4 Special warnings and precautions for use and 4.8 Adverse effects (undesirable effects)).

In clinical trials, the following laboratory results were observed:

- Cyclic fluctuations in the neutrophil counts were frequently observed in patients with congenital or idiopathic neutropenia after initiation of NEUPOGEN therapy.
- Platelet counts were generally at the upper limits of normal prior to NEUPOGEN therapy. With NEUPOGEN therapy, platelet counts decreased but generally remained within normal limits (see Section 4.8 Adverse effects (undesirable effects)).
- Early myeloid forms were noted in peripheral blood in most patients, including the appearance of metamyelocytes and myelocytes. Promyelocytes and myeloblasts were noted in some patients.
- Relative increases were occasionally noted in the number of circulating eosinophils and basophils. No consistent increases were observed with NEUPOGEN therapy.

### **Patients with HIV infection**

Absolute neutrophil count should be monitored closely, especially during the first few weeks of NEUPOGEN therapy. Some patients may respond very rapidly with a considerable increase in neutrophil count after initial doses of NEUPOGEN. It is recommended that the ANC is measured daily for the first 2 to 3 days of NEUPOGEN administration. Thereafter, it is recommended that the ANC is measured at least twice

---

per week for the first 2 weeks and subsequently once per week or once every other week during maintenance therapy. During intermittent dosing with 300 µg of NEUPOGEN, there will be wide fluctuations in the patient's ANC over time. In order to determine a patient's trough or nadir ANC, it is recommended that blood samples for ANC measurement are obtained immediately prior to any scheduled dosing with NEUPOGEN.

### **Use in the elderly**

No data available.

### **Paediatric use**

Long-term follow-up data are available from a postmarketing surveillance study in SCN patients including 32 infants, 200 children and 68 adolescents. The data suggest that height and weight are not adversely affected in paediatric patients who received up to 5 years of NEUPOGEN treatment. Limited data from patients who were followed in a phase 3 study to assess the safety and efficacy of NEUPOGEN in SCN for 1.5 years did not suggest alterations in sexual maturation or endocrine function.

Paediatric patients with congenital types of neutropenia (Kostmann's syndrome, congenital agranulocytosis, or Schwachman-Diamond syndrome) have developed cytogenetic abnormalities and have undergone transformation to MDS and AML while receiving chronic NEUPOGEN treatment. The relationship of these events to NEUPOGEN administration is unknown (see Section 4.2 Dose and method of administration and 4.8 Adverse effects (undesirable effects)).

Although use in children with AML is not excluded, published experience is limited and safety has not been clearly established.

### **Effects on laboratory tests**

Not known.

## **4.5 Interactions with other medicines and other forms of interactions**

### **Bone imaging**

Increased haematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes. This should be considered when interpreting bone-imaging results.

---



## **Lithium**

The potential for pharmacodynamic interaction with lithium, which also promotes the release of neutrophils, has not been specifically investigated. There is no evidence that such an interaction would be harmful.

## **4.6 Fertility, pregnancy and lactation**

### **Effects on fertility**

NEUPOGEN had no observed effect on the fertility of male or female rats, or gestation at doses up to 500 µg/kg. No human data are available.

### **Use in Pregnancy**

#### **Pregnancy Category B3**

There are no company sponsored studies of the use of NEUPOGEN in pregnant women. However, there are cases in the literature where the transplacental passage of NEUPOGEN has been demonstrated. NEUPOGEN should not be used during pregnancy unless the potential benefit outweighs the potential risk to the fetus.

Reproductive studies in pregnant rats have shown that NEUPOGEN was not associated with lethal, teratogenic or behavioural effects on fetuses when administered by daily IV injection during the period of organogenesis at dose levels up to 575 µg/kg/day (see Section 5.3 Preclinical safety data, Teratogenicity).

### **Use in Lactation**

It is not known whether NEUPOGEN is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised in the use of NEUPOGEN in nursing women.

## **4.7 Effects on ability to drive and use machines**

The effects of this medicine on a person's ability to drive and use machines were not assessed as part of its registration.

## **4.8 Adverse effects (undesirable effects)**

### **Cancer patients receiving myelosuppressive chemotherapy**

In clinical trials involving over 200 patients receiving NEUPOGEN following cytotoxic chemotherapy, most adverse experiences were the sequelae of the underlying

---

malignancy or cytotoxic chemotherapy. In all phase 2/3 trials, medullary bone pain was the only consistently observed adverse reaction attributed to NEUPOGEN therapy, reported in 24% of patients. This bone pain was generally reported to be of mild-to-moderate severity and could be controlled in most patients with non-narcotic analgesics. Infrequently, bone pain was severe enough to require narcotic analgesics. Bone pain was reported more frequently in patients treated with higher doses (20 to 100 µg/kg/day) administered IV and less frequently in patients treated with lower SC doses of NEUPOGEN (3 to 10 µg/kg/day).

In the randomised, double-blind, placebo-controlled trial of NEUPOGEN therapy following combination chemotherapy in patients with small cell lung cancer, the following adverse events were reported to be possibly, probably, or definitely related to the double-blind study medication (placebo or NEUPOGEN at 4 to 8 µg/kg/day):

<b>Clinical Adverse Events by Body System Reported to be Related to Double-blind Study Medication</b>		
Body System	% of Patients with Reported Events	
	Placebo N = 68	NEUPOGEN N = 69
Musculoskeletal	1.5	12.0
Integumentary	6.0	6.0
Body as a Whole	5.0	4.3
Neurologic/Psychiatric	3.0	4.3
Respiratory	1.5	3.0
Vascular Disorders	1.5	3.0
Local Reaction	1.5	1.4
Thrombocytopenia/Coagulation	2.9	NR
Autonomic Nervous System	NR	1.4
Special Senses	NR	1.4

NR = not reported

In this study, there were no serious, life-threatening or fatal adverse reactions attributed to NEUPOGEN therapy. Specifically, there were no reports of flu-like symptoms, pleuritis, pericarditis or other major systemic reactions to NEUPOGEN.

Spontaneously reversible elevations in uric acid, lactate dehydrogenase and alkaline phosphatase occurred in 26% to 56% of patients receiving NEUPOGEN following cytotoxic chemotherapy. These elevations were not reported to be associated with clinical adverse events.

The occurrence of stomatitis and diarrhoea in patients receiving allogeneic transplants is consistent with the use of myeloablative chemotherapy. In a study of 70 patients undergoing allogeneic bone marrow transplantation in which 33 patients were randomised to the placebo group and 37 to the filgrastim group, the incidence and severity of diarrhoea and stomatitis increased from the pre- to the post-transplant period in both the placebo and filgrastim treated patients. Prior to transplantation, 12 patients randomised to the placebo group and 6 patients randomised to filgrastim reported moderate-to-severe diarrhoea. Following transplantation, the incidence of moderate-to-severe diarrhoea increased to 23 and 14 patients respectively. No patients in either group experienced moderate or severe stomatitis prior to transplantation, while after transplantation, 19 patients in the placebo group and 8 patients in the filgrastim group reported moderate-to-severe stomatitis.

In a randomised, double-blind, placebo-controlled phase 3 study of patients with AML, there were 3 patients reported to have developed ARDS during the study (2 NEUPOGEN, 1 placebo). This is a rare but expected event in this patient population, and all 3 patients had recognised predisposing factors. As a causal relationship between the development of ARDS and NEUPOGEN treatment has not been established, and as multiple risk factors are often present, any decision to discontinue NEUPOGEN in this setting should be based on the overall assessment of contributing factors.

Extremely rare cases of capillary leak syndrome have been reported.

Rare cases ( $\leq 1/10,000$  to  $< 1/1,000$ ) of Sweet's syndrome (acute febrile neutrophilic dermatosis) have been reported.

Very rare (estimated 0.03 cases per 100,000 exposures [0.00003%]) events of chondrocalcinosis pyrophosphate have been reported in patients with cancer treated with filgrastim.

### **Chronic administration**

With chronic administration, clinical splenomegaly has been reported in 30% of patients. Less frequently observed adverse events included exacerbation of some pre-existing skin disorders (e.g. psoriasis), cutaneous vasculitis (leukocytoclastic), alopecia, haematuria/proteinuria, thrombocytopenia (platelets  $< 50 \times 10^9/L$ ) and osteoporosis. Patients receiving chronic treatment with NEUPOGEN should be monitored periodically for the appearance of these conditions.

---

No evidence of interaction of NEUPOGEN with other drugs was observed in the course of clinical trials (see Section 4.4 Special warnings and precautions for use). Since commercial introduction of NEUPOGEN there have been rare reports (< 1 in 100,000 administrations) of symptoms suggestive of allergic-type reactions such as anaphylactic reactions, dyspnoea, hypotension, skin rash, and urticaria, but in which an immune component has not been demonstrated. Approximately half occurred following the initial dose; reactions occurred more frequently with IV administration. Symptoms recurred in some patients rechallenged. There have been rare reports (< 1 in 500,000 administrations) of cutaneous vasculitis. NEUPOGEN should be permanently discontinued in patients who experience a serious allergic reaction.

In chronically treated patients, including some who have received NEUPOGEN daily for almost 2 years, there has been no evidence of the development of antibodies to NEUPOGEN or a blunted or diminished response over time.

### **Peripheral blood progenitor cell collection and therapy**

#### **NEUPOGEN-mobilised autologous PBPC collection**

In clinical trials, 126 patients have received NEUPOGEN for mobilisation of PBPCs. During the mobilisation period, adverse events related to NEUPOGEN consisted primarily of mild-to-moderate musculoskeletal symptoms, reported in 44% of patients. These symptoms were predominantly events of medullary bone pain (38%). Headache was reported related to NEUPOGEN in 7% of patients. Mild-to-moderate transient increases in alkaline phosphatase levels were reported related to NEUPOGEN in 21% of the patients who had serum chemistries evaluated during the mobilisation phase.

All patients had increases in neutrophil counts consistent with the biological effects of NEUPOGEN. Two patients had a WBC count greater than  $100 \times 10^9/L$  with WBC count increases during the mobilisation period ranging from  $16.7$  to  $138 \times 10^9/L$  above baseline. Eighty-eight percent of patients had an increase in WBC count between  $10$  and  $70 \times 10^9/L$  above baseline. No clinical sequelae were associated with any grade of leukocytosis.

Sixty-five percent of patients had downward shifts in haemoglobin, which were generally mild-to-moderate (59%) and 97% of patients had decreases in platelet counts related to the leukapheresis procedure. Only 2 patients had platelet counts less than  $50 \times 10^9/L$ .

---

**Allogeneic peripheral blood progenitor cell mobilisation in normal donors**

The most commonly reported adverse event was mild-to-moderate transient musculoskeletal pain. Leukocytosis ( $WBC > 50 \times 10^9/L$ ) was observed in 41% of donors and transient thrombocytopenia (platelets  $< 100 \times 10^9/L$ ) following NEUPOGEN and leukapheresis was observed in 35% of donors.

Transient, minor increases in alkaline phosphatase, LDH, AST and uric acid have been reported in normal donors receiving NEUPOGEN; these were without clinical sequelae.

Exacerbation of arthritic symptoms has been observed very rarely.

Symptoms suggestive of severe allergic reactions have been reported very rarely.

Headaches, believed to be caused by NEUPOGEN, have been reported in PBPC donor studies.

There have been uncommon ( $\geq 1/1000$  and  $< 1/100$ ) cases of splenic rupture reported in normal donors receiving G-CSFs (see Section 4.4 Special warnings and precautions for use).

Extremely rare cases of capillary leak syndrome have been reported.

In normal donors, pulmonary adverse events (haemoptysis, lung infiltration) have been reported.

**PBPC transplantation supported by NEUPOGEN**

During the period of NEUPOGEN administration post infusion of autologous PBPCs, NEUPOGEN was administered to 110 patients as supportive therapy and adverse events were consistent with those expected after high-dose chemotherapy. Mild-to-moderate musculoskeletal pain was the most frequently reported adverse event related to NEUPOGEN, reported in 15% of patients. In patients receiving allogeneic PBPCs, a similar incidence of musculoskeletal pain was reported.

**Patients with severe chronic neutropenia**

The safety and efficacy of chronic daily administration of NEUPOGEN in patients with SCN have been established in phase 1/2 clinical trials of 74 patients treated for up to 3 years and in a phase 3 trial of 123 patients treated for up to 2 years.

Mild-to-moderate bone pain was reported in approximately 33% of patients in clinical trials. This symptom was readily controlled with mild analgesics. General musculoskeletal pain was also noted in higher frequency in patients treated with

---

NEUPOGEN. Palpable splenomegaly was observed in approximately 30% of patients. Abdominal or flank pain was seen infrequently and thrombocytopenia ( $< 50 \times 10^9/L$ ) was noted in 12% of patients with palpable spleens. Less than 3% of all patients underwent splenectomy and most of these had a prestudy history of splenomegaly. Less than 6% of patients had thrombocytopenia ( $< 50 \times 10^9/L$ ) during NEUPOGEN therapy, most of whom had a prestudy history. In most cases, thrombocytopenia was managed by NEUPOGEN dose reduction or interruption. There were no associated serious haemorrhagic sequelae in these patients. Epistaxis was noted in 15% of patients treated with NEUPOGEN but was associated with thrombocytopenia in 2% of patients. Anaemia was reported in approximately 10% of patients, but in most cases appeared to be related to frequent diagnostic phlebotomy, chronic illness or concomitant medications.

Cytogenetic abnormalities, transformation to MDS and AML have been observed in patients treated with NEUPOGEN for SCN (see Section 4.4 Special warnings and precautions for use). Based on analysis of data from a postmarketing surveillance study of 531 SCN patients with an average follow-up of 4.0 years, the risk of developing these abnormalities (cytogenetic abnormalities, MDS and AML) appears to be confined to the subset of patients with congenital neutropenia. A life-table analysis of these data revealed that the cumulative risk of developing leukaemia or MDS by the end of the 8<sup>th</sup> year of NEUPOGEN treatment in a patient with congenital neutropenia was 16.5% which is an annual rate of approximately 2%.

Cytogenetic abnormalities, including monosomy 7, have been reported in patients treated with NEUPOGEN who had previously documented normal cytogenetic evaluations. It is unknown whether the development of cytogenetic abnormalities, MDS or AML is related to chronic daily NEUPOGEN administration or to the natural history of SCN. It is also unknown if the rate of conversion in patients who have not received NEUPOGEN is different from that of patients who have received NEUPOGEN. Routine monitoring through regular FBCs is recommended for all SCN patients. Additionally, annual bone marrow and cytogenetic evaluations are recommended in all patients with congenital neutropenia (see Section 4.4 Special warnings and precautions for use).

Other adverse events infrequently observed and possibly related to NEUPOGEN therapy were: injection site reaction, headache, hepatomegaly, arthralgia, osteoporosis, rash, alopecia, cutaneous vasculitis and haematuria/proteinuria. Patients receiving chronic

treatment with NEUPOGEN should be monitored periodically for the appearance of these conditions.

In postmarketing experience, common cases of decreased bone density and osteoporosis have been reported in paediatric patients with SCN receiving chronic treatment with NEUPOGEN.

### **Patients with HIV infection**

In 3 clinical studies involving a total of 244 HIV-positive patients, the only adverse events that were consistently considered related to NEUPOGEN administration were musculoskeletal pain, predominantly mild-to-moderate bone pain and myalgia. In the largest of the 3 studies involving 200 patients, the event rate was 12%. This is consistent with the 14% incidence of musculoskeletal pain reported in clinical trials in other indications where doses of 0.35 to 11.5 µg/kg/day were used. The incidence of severe musculoskeletal pain (3%) was identical to that reported in clinical trials in other indications.

In a small study of 24 patients, there were 7 reports of treatment-related splenomegaly, but in a larger study of 200 patients, there were no such reports. In the former study, no baseline measurements of spleen size were made for comparison with on-study measurements. In all cases, splenomegaly was mild or moderate on physical examination and the clinical course was benign; no patients had a diagnosis of hypersplenism and no patients underwent splenectomy. As splenic enlargement is a common finding in patients with HIV infection and is present to varying degrees in most patients with AIDS, the relationship to NEUPOGEN treatment is unclear.

An analysis was performed on viral load data, as measured by HIV-1 RNA polymerase chain reaction (PCR), from a controlled randomised study of NEUPOGEN for the prevention of grade 4 neutropenia. No clinically or statistically significant differences were seen between NEUPOGEN treated groups and untreated groups for changes in viral load over a 24-week period. However, since the study was not powered to show equivalence between the groups, the possibility that NEUPOGEN affects HIV-1 replication can not be excluded. There was also no detrimental effect on immunological markers, which is important in a population of patients in whom a decline in CD4<sup>+</sup> T-lymphocyte count is expected. There were no safety concerns with long-term administration of NEUPOGEN in this setting.

---

**Adverse reactions relevant to all indications**

In combined clinical trials in the Amgen development program, adverse reactions are listed below. Adverse reactions observed in the combined clinical trial data which are present in the adverse effects sections by indication above, are not included in this list:

Very common ( $\geq 1/10$ ) nausea, vomiting, pyrexia, fatigue, and headache.

Common ( $\geq 1/100$  and  $< 1/10$ ) hypertension, pain, oral pain, oropharyngeal pain, haemoptysis, chest pain, back pain, arthralgia, asthenia, malaise, cough, oedema peripheral, decreased appetite, constipation, sepsis, bronchitis, upper respiratory tract infection, urinary tract infection, muscle spasms, dizziness, hypoaesthesia, paraesthesia, insomnia, erythema, and transfusion reaction.

Uncommon ( $\geq 1/1000$  and  $< 1/100$ ) hypersensitivity, lung infiltration and rash maculopapular.

Rare ( $\geq 1/10,000$  and  $< 1/1,000$ ) glomerulonephritis.

**Postmarketing experience relevant to all indications**

Cases of splenomegaly have been reported commonly ( $\geq 1/100$  and  $< 1/10$ ) in patients treated with NEUPOGEN.

Cases of splenic rupture, sickle cell anaemia with crisis and glomerulonephritis have been reported uncommonly ( $\geq 1/1000$  and  $< 1/100$ ) in patients treated with NEUPOGEN.

Cases of pulmonary haemorrhage, pulmonary infiltrates, and haemoptysis have been reported in patients receiving NEUPOGEN.

Cases of aortitis have been reported in patients receiving NEUPOGEN.

Cases of myelodysplastic syndrome and acute myeloid leukaemia have been reported in breast cancer patients receiving NEUPOGEN in conjunction with chemotherapy and/or radiotherapy.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at <http://www.tga.gov.au/reporting-problems>

---



## 4.9 Overdose

The maximum tolerated dose of NEUPOGEN has not been determined. Twenty-seven patients have been treated at NEUPOGEN doses of  $\geq 69 \mu\text{g}/\text{kg}/\text{day}$ . Of those, 6 patients have been treated at  $115 \mu\text{g}/\text{kg}/\text{day}$  with no toxic effects attributable to NEUPOGEN. Efficacy has been demonstrated using much lower doses (doses of 4 to  $8 \mu\text{g}/\text{kg}/\text{day}$  showed efficacy in the phase 3 study). Doses of NEUPOGEN which increase the ANC beyond  $10 \times 10^9/\text{L}$  may not result in any additional clinical benefit.

In clinical trials of NEUPOGEN in cancer patients receiving myelosuppressive chemotherapy, WBC counts  $> 100 \times 10^9/\text{L}$  have been reported in less than 5% of patients, but were not associated with any reported adverse clinical effects.

It is recommended, to avoid the potential risks of excessive leukocytosis, that NEUPOGEN therapy should be discontinued if the ANC surpasses  $10 \times 10^9/\text{L}$  after the chemotherapy-induced ANC nadir has occurred.

In cancer patients receiving myelosuppressive chemotherapy, discontinuation of NEUPOGEN therapy usually results in a 50% decrease in circulating neutrophils within 1 to 2 days, with a return to pretreatment levels in 1 to 7 days.

For information on the management of overdose, contact the Poison Information Centre on 131126 (Australia).

## 5 PHARMACOLOGICAL PROPERTIES

### 5.1 Pharmacodynamic properties

#### Mechanism of action

Colony stimulating factors are glycoproteins which act on haemopoietic cells by binding to specific cell surface receptors and stimulating proliferation, differentiation commitment and some end-cell functional activation.

Endogenous filgrastim is a lineage-specific colony stimulating factor with selectivity for the neutrophil lineage. Filgrastim is not species specific and has been shown to primarily affect neutrophil progenitor proliferation, differentiation and selected end-cell functional activation (including enhanced phagocytic ability, priming of the cellular metabolism associated with respiratory burst, antibody dependent killing and the increased expression of some functions associated with cell surface antigens).

---

## **Clinical trials**

### **Cancer Patients Receiving Myelosuppressive Chemotherapy**

In all clinical studies, administration of NEUPOGEN resulted in a dose-dependent rise in neutrophil counts. Following termination of NEUPOGEN therapy, circulating neutrophil counts declined by 50% within 1 to 2 days and to pretreatment levels within 1 to 7 days. Isolated neutrophils displayed normal phagocytic and chemotactic activity *in vitro*.

In a study of the effects of NEUPOGEN in patients with carcinoma of the urothelium, repeated daily IV dosing with NEUPOGEN resulted in a linear dose-dependent increase in circulating neutrophil counts over the dose range of 1 to 70 µg/kg/day. The effects of NEUPOGEN therapy reversed within 24 hours of the termination of administration and neutrophil counts returned to baseline, in most cases, within 4 days.

In a phase 1 study of patients with a variety of malignancies, including lymphoma, multiple myeloma and adenocarcinoma of the lung, breast and colon, NEUPOGEN induced a dose-dependent increase in neutrophil counts. This increase in neutrophil counts was observed whether NEUPOGEN was administered intravenously (1 to 70 µg/kg twice daily), SC (1 to 3 µg/kg once daily) or by continuous SC infusion (3 to 11 µg/kg/day).

These results were consistent with a phase 1 study of patients with small cell lung cancer who were administered NEUPOGEN prior to chemotherapy. All patients responded to NEUPOGEN (1 to 45 µg/kg/day), given for 5 days, with a dose-dependent increase in median neutrophil count from a baseline of  $9.5 \times 10^9/L$  to a maximum response of  $43 \times 10^9/L$ .

In a randomised, double-blind, placebo-controlled phase 3 study of small cell lung cancer patients receiving combination chemotherapy (cyclophosphamide, doxorubicin and etoposide), treatment with NEUPOGEN resulted in clinically and statistically significant reductions in both the incidence and duration of infection, as manifested by febrile neutropenia. The incidence, severity and duration of severe neutropenia ( $ANC < 0.5 \times 10^9/L$ ) following chemotherapy were all significantly reduced, as were the requirements for in-patient hospitalisation and antibiotic use (see Section 4.8 Adverse effects (undesirable effects)). With other myelosuppressive regimens (e.g. M-VAC, melphalan), a dose-dependent increase in neutrophil counts was observed, as well as a decrease in the duration of severe neutropenia.

---

In a randomised, double-blind, placebo-controlled phase 3 study of patients with AML, the median duration of neutropenia ( $ANC < 0.5 \times 10^9/L$ ) during the first induction cycle was significantly reduced, from 19 days in the placebo group to 14 days in the NEUPOGEN group. The duration of hospitalisation during induction therapy was also significantly reduced in the NEUPOGEN group, from 29 days to 23 days, as were the duration of fever and incidence of IV antibiotic use. NEUPOGEN had a similar impact on the durations of neutropenia, hospitalisation, fever and IV antibiotic use in subsequent cycles of chemotherapy.

The absolute monocyte count was reported to increase in a dose-dependent manner in most patients receiving NEUPOGEN. The percentage of monocytes in the differential count was within the normal range. In all studies to date, absolute counts of both eosinophils and basophils were within the normal range following administration of NEUPOGEN. Small non-dose-dependent increases in lymphocyte counts following NEUPOGEN administration have been reported in normal subjects and cancer patients.

### **Peripheral Blood Progenitor Cell (PBPC) Collection and Therapy**

Use of NEUPOGEN, either alone, or after chemotherapy, mobilises haemopoietic progenitor cells into the peripheral blood. These peripheral blood progenitor cells (PBPCs) may be harvested and infused after high-dose chemotherapy, either in place of, or in addition to bone marrow transplantation. Infusion of PBPCs accelerates the rate of neutrophil and platelet recovery reducing the risk of haemorrhagic complications and the need for platelet transfusions.

In a randomised phase 3 study of patients with Hodgkin's disease or non-Hodgkin's lymphoma undergoing myeloablative chemotherapy, 27 patients received autologous NEUPOGEN-mobilised peripheral blood progenitor cell transplantation (PBPCT) followed by NEUPOGEN  $5 \mu\text{g}/\text{kg}/\text{day}$  and 31 patients received autologous bone marrow transplantation (ABMT) followed by NEUPOGEN  $5 \mu\text{g}/\text{kg}/\text{day}$ . Patients randomised to the NEUPOGEN-mobilised PBPCT group compared to the ABMT group had significantly fewer median days of platelet transfusions (6 vs 10 days), a significantly shorter median time to a sustained platelet count  $> 20 \times 10^9/L$  (16 vs 23 days), a significantly shorter median time to recovery of a sustained  $ANC \geq 0.5 \times 10^9/L$  (11 vs 14 days) and a significantly shorter duration of hospitalisation (17 vs 23 days).

---

In all clinical trials of NEUPOGEN for the mobilisation of PBPCs, NEUPOGEN (5 to 24 µg/kg/day) was administered following infusion of the cells until a sustainable ANC ( $\geq 0.5 \times 10^9/L$ ) was reached.

Overall, infusion of NEUPOGEN-mobilised PBPCs, supported by NEUPOGEN post-transplantation, provided rapid and sustained haematologic recovery. Long-term (approximately 100 days) follow-up haematology data from patients treated with autologous PBPCT alone or in combination with bone marrow was compared to historical data from patients treated with ABMT alone. This retrospective analysis indicated that engraftment is durable.

In a randomised trial comparing NEUPOGEN-mobilised allogeneic PBPCT with allogeneic BMT in patients with acute leukaemia, chronic myelogenous leukaemia or myelodysplastic syndrome, NEUPOGEN was given at 10 µg/kg/day to 163 healthy volunteers for 4 to 5 days followed by leukapheresis beginning on day 5. Another 166 healthy volunteers donated bone marrow. The number of CD34<sup>+</sup> cells in the leukapheresis product was generally sufficient to support a transplant, with over 80% of donors achieving the target yield of  $4 \times 10^6/kg$  recipient bodyweight. In the vast majority of donors (95%) sufficient PBPCs ( $2 \times 10^6$  CD34<sup>+</sup> cells/kg of recipient) were obtained in  $\leq 2$  leukaphereses. The median number of CD34<sup>+</sup> cells in the leukapheresis product ( $5.8 \times 10^6/kg$ ) was higher than that of bone marrow product ( $2.7 \times 10^6/kg$ ); however, the product from both procedures was sufficient to allow each recipient to receive a transplant. Following transplant, all recipients received NEUPOGEN at 5 µg/kg/day until neutrophil recovery (up to 28 days). Recipients of allogeneic PBPC had a shorter median time to platelet recovery of  $\geq 20 \times 10^9/L$  (15 vs 20 days) and shorter median time to ANC recovery of  $\geq 0.5 \times 10^9/L$  (12 vs 15 days). There was no difference in leukaemia free survival at a median follow-up of 12 months.

### **Patients with severe chronic neutropenia (SCN)**

In a randomised, controlled, open-label phase 3 trial of 123 patients with idiopathic, cyclic and congenital neutropenia, untreated patients had a median ANC of  $0.21 \times 10^9/L$ . NEUPOGEN therapy was adjusted to maintain the median ANC between 1.5 and  $10 \times 10^9/L$ . A complete response was seen in 88% of patients (defined as a median ANC  $\geq 1.5 \times 10^9/L$ ) over 5 months of NEUPOGEN therapy. Overall, the response to NEUPOGEN therapy for all patients was observed in 1 to 2 weeks. The median ANC after 5 months of NEUPOGEN therapy for all patients was  $7.46 \times 10^9/L$ .

(range 0.03 to 30.88 x 10<sup>9</sup>/L). In general, patients with congenital neutropenia responded to NEUPOGEN therapy with lower median ANC than patients with idiopathic or cyclic neutropenia.

Overall, daily treatment with NEUPOGEN resulted in clinically and statistically significant reductions in the incidence and duration of fever, infections and oropharyngeal ulcers. As a result, there also were substantial decreases in requirements for antibiotic use and hospitalisation. Additionally, patients treated with NEUPOGEN reported fewer episodes of diarrhoea, nausea, fatigue and sore throat.

### **Patients with HIV infection**

In an open-label, non-comparative study involving 200 HIV-positive patients with neutropenia (ANC < 1.0 x 10<sup>9</sup>/L), NEUPOGEN reversed the neutropenia in 98% of patients (ANC ≥ 2.0 x 10<sup>9</sup>/L) with a median time to reversal of 2 days (range 1 to 16) and a median dose of 1 µg/kg/day (range 0.5 to 10). Ninety-six percent of patients achieved reversal of neutropenia with a dose of ≤ 300 µg/day. Normal ANCs were then maintained with a median dose frequency of 3 times 300 µg vials/week (range 1 to 7). Ganciclovir, zidovudine, co-trimoxazole and pyrimethamine were the medications most frequently considered to be causing neutropenia and 83% of patients received 1 or more of these on-study. During the study, 84% of these patients were able to increase or maintain dosing of these 4 medications or add them to their therapy. The number of these 4 medications received per patient increased by more than 20% (from 0.98 to 1.18) during NEUPOGEN therapy. The median duration of NEUPOGEN treatment was 191 days (range 2 to 815). One hundred fifty-three patients received long-term maintenance therapy (> 58 days) and the frequency of dosing was similar to that in the first 30 days of maintenance therapy (71% of patients were receiving 2 to 3 vials per week).

Overall, in patients with HIV infection NEUPOGEN rapidly reverses neutropenia and is subsequently able to maintain normal neutrophil counts during chronic administration.

## **5.2 Pharmacokinetic properties**

In normal volunteers, serum NEUPOGEN concentrations declined monoexponentially following a single intravenous (IV) infusion, exhibiting a half-life of approximately 3 hours. Clearance and volume of distribution averaged 0.6 mL/minute/kg and 163 mL/kg. Following a single SC injection, peak serum concentrations of NEUPOGEN occurred at

approximately 4 to 6 hours. The absorption phase can be fitted to either a zero-order or a first-order model whereas the elimination phase observed a monoexponential decline. No difference in half-lives were observed following IV and SC doses. The bioavailability was estimated to be approximately 50% following SC administration.

In cancer patients, clearance and volume of distribution of NEUPOGEN were found to be lower than in normal volunteers, averaging approximately 0.12 to 0.34 mL/minute/kg and 56 to 127 mL/kg, respectively. However, the elimination half-life appeared to be similar when compared to normal volunteers, averaging 3 to 4 hours. Following a single SC injection of 3.45 µg/kg and 11.5 µg/kg, peak serum concentrations occurred at approximately 4 to 5 hours and averaged 4 ng/mL and 49 ng/mL. Continuous SC infusions of 23 µg/kg of NEUPOGEN over 24 hours in cancer patients resulted in a steady-state concentration of approximately 50 (30 to 70) ng/mL. No evidence of drug accumulation was observed over 11 to 20 days of continuous infusion. When a single IV dose (1.73 to 69 µg/kg) was administered to cancer patients, the area under the serum concentration-time curves increased proportional to the dose. Serum concentrations of NEUPOGEN were found to decrease in paediatric cancer patients who were dosed at 5 to 15 µg/kg/day for 10 days. The decrease of serum concentrations may be associated with a change in the clearance of NEUPOGEN due to increasing neutrophil counts.

Subcutaneous injections of NEUPOGEN solutions containing either sorbitol or mannitol resulted in similar pharmacokinetic profiles and response in absolute neutrophil counts (ANC). When a single 5 µg/kg SC dose was administered to normal subjects using 3 concentrations of NEUPOGEN solution (300, 600 and 960 µg/mL), the 3 concentrations were found to be equivalent in elevating ANC. Although increased maximum serum concentration and area under the serum concentration curve were observed with increasing NEUPOGEN concentrations, these pharmacokinetic differences did not correlate with biological response.

### **Preclinical studies**

The results of all preclinical studies indicate that the pharmacologic effects of NEUPOGEN are consistent with its predominant role as a regulator of neutrophil production and function.

---

### 5.3 Preclinical safety data

#### **Cell proliferation potential**

As with other haematopoietic growth factors, G-CSF has shown *in vitro* stimulating properties on human endothelial cells. G-CSF can promote growth of myeloid cells, including malignant cells, *in vitro*, and similar effects may be seen on some non-myeloid cells *in vitro*.

#### **Genotoxicity**

In either the presence or absence of a drug enzyme metabolising system, NEUPOGEN failed to induce chromosomal aberrations (in Chinese hamster lung cells *in vitro*) or bacterial gene mutations. NEUPOGEN was negative in an *in vivo* mouse micronuclear test. NEUPOGEN failed to induce bacterial gene mutations in either the presence or absence of a drug metabolising enzyme system.

#### **Carcinogenicity**

The carcinogenic potential of NEUPOGEN has not been studied.

#### **Teratogenicity**

The administration of NEUPOGEN to pregnant rabbits during the period of organogenesis at doses of 20 µg/kg/day IV or greater was associated with an increased incidence of embryonic loss, urogenital bleeding and decreased food consumption. External abnormalities were not observed in the fetuses of treated does, but there was a significant increase in the incidence of fusion of sternebrae at an 80 µg/kg/day dose. The administration of NEUPOGEN to pregnant rabbits at a dose of 5 µg/kg/day IV was not associated with observable adverse effects to the doe or fetus (see Section 4.6 Fertility, pregnancy and lactation, Use in pregnancy).

## 6 PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

Each single use pre-filled syringe and vial contains:

Acetate

Sorbitol

Polysorbate 80

Sodium

Water for injections

---

## 6.2 Incompatibilities

Do not dilute with saline at any time; product may precipitate.

## 6.3 Shelf life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

## 6.4 Special precautions for storage

NEUPOGEN should be stored in the refrigerator at 2° to 8°C (36° to 46°F). A single brief period (up to 3 days) of exposure to room temperature (up to 30°C) or exposure to freezing temperatures (as low as -20°C) does not adversely affect the stability of NEUPOGEN. Avoid vigorous shaking.

### **NEUPOGEN Dilutions**

Solutions withdrawn under aseptic conditions, such as a laminar flow hood, may be stored in polypropylene syringes at 2° to 8°C (36° to 46°F) for up to 24 hours before use. To reduce the possibility of microbiological hazard from product manipulation, storage for longer periods is not recommended due to the compromised condition of this patient population in regard to infection.

Diluted NEUPOGEN should not be prepared more than 24 hours before administration and should be stored in the refrigerator at 2° to 8°C (36° to 46°F). Prior to injection, NEUPOGEN may be allowed to reach room temperature.

## 6.5 Nature and contents of container

Filgrastim is supplied in Type I glass vials and Type I glass pre-filled syringes.

The vial stopper and needle cover for the pre-filled syringe contains dry natural rubber (a derivative of latex).

NEUPOGEN 300 µg/0.5 mL syringe for SC or IV injection: Single use, preservative-free syringes containing 300 µg (0.5 mL) of filgrastim (600 µg/mL). Boxes of 10.

NEUPOGEN 480 µg/0.5 mL syringe for SC or IV injection: Single use, preservative-free syringes containing 480 µg (0.5 mL) of filgrastim (960 µg/mL). Boxes of 10.

NEUPOGEN 300 µg/1 mL vial for SC or IV injection: Single use, preservative-free vials containing 300 µg (1 mL) of filgrastim (300 µg/mL). Boxes of 10.

---



NEUPOGEN 480 µg/1.6 mL vial for SC or IV injection: Single use, preservative-free vials containing 480 µg (1.6 mL) of filgrastim (300 µg/mL). Boxes of 10.

## 6.6 Special precautions for disposal

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

## 6.7 Physicochemical properties

### Chemical structure

NEUPOGEN (filgrastim) is a 175 amino acid protein manufactured by recombinant DNA technology. NEUPOGEN is produced by *Escherichia coli* bacteria into which has been inserted the human granulocyte colony stimulating factor (G-CSF) gene. It has a molecular weight of 18,800 daltons. NEUPOGEN is unglycosylated and contains an N-terminal methionine necessary for expression in *E coli*.

The specific activity of NEUPOGEN by *in vitro* proliferative cell assay is  $1 \times 10^8$  IU/mg when assayed against the WHO international standard for granulocyte colony stimulating factor, 88/502. The clinical significance of this *in vitro* potency assignment is unknown.

## 7 MEDICINE SCHEDULE (POISONS STANDARD)

S4 Prescription medicine

---

## 8 SPONSOR

### NAME AND ADDRESS OF SPONSOR

Amgen Australia Pty Ltd  
ABN 31 051 057 428  
Level 7, 123 Epping Road  
NORTH RYDE NSW 2113

## 9 DATE OF FIRST APPROVAL

13 November 1995

## 10 DATE OF REVISION

21 October 2020

### SUMMARY TABLE OF CHANGES

Section changed	Summary of new information
4.4	Addition of MDS/AML in breast cancer patients
4.8	Addition of MDS/AML in breast cancer patients
4.8	Changes to description of data from Amgen development program

©1991-2020 Amgen Inc. All rights reserved.

---